Pier Capital LLC Sells 17,704 Shares of Tabula Rasa HealthCare Inc (TRHC)

Pier Capital LLC decreased its position in shares of Tabula Rasa HealthCare Inc (NASDAQ:TRHC) by 11.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 133,614 shares of the company’s stock after selling 17,704 shares during the quarter. Tabula Rasa HealthCare makes up about 1.2% of Pier Capital LLC’s portfolio, making the stock its 15th biggest holding. Pier Capital LLC owned approximately 0.67% of Tabula Rasa HealthCare worth $8,529,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Koch Industries Inc. acquired a new position in Tabula Rasa HealthCare in the first quarter valued at about $244,000. Principal Financial Group Inc. acquired a new position in Tabula Rasa HealthCare in the first quarter valued at about $3,870,000. The Manufacturers Life Insurance Company lifted its position in Tabula Rasa HealthCare by 18.5% in the first quarter. The Manufacturers Life Insurance Company now owns 9,297 shares of the company’s stock valued at $360,000 after buying an additional 1,453 shares during the last quarter. Westwood Management Corp IL acquired a new position in Tabula Rasa HealthCare in the second quarter valued at about $849,000. Finally, Dana Investment Advisors Inc. acquired a new position in Tabula Rasa HealthCare in the second quarter valued at about $2,557,000. 68.88% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:TRHC opened at $71.11 on Thursday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 0.33 and a current ratio of 0.36. The stock has a market cap of $1.34 billion, a price-to-earnings ratio of -1,777.75, a price-to-earnings-growth ratio of 5.15 and a beta of 2.03. Tabula Rasa HealthCare Inc has a 1 year low of $17.01 and a 1 year high of $72.64.

Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its quarterly earnings results on Tuesday, August 7th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.08 by $0.12. The company had revenue of $48.60 million for the quarter, compared to analyst estimates of $46.73 million. Tabula Rasa HealthCare had a negative net margin of 16.78% and a positive return on equity of 4.55%. analysts anticipate that Tabula Rasa HealthCare Inc will post 0.52 EPS for the current fiscal year.

In other Tabula Rasa HealthCare news, CEO Calvin H. Knowlton sold 8,000 shares of the business’s stock in a transaction dated Tuesday, August 7th. The shares were sold at an average price of $60.54, for a total transaction of $484,320.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Bruce Luehrs sold 85,842 shares of the business’s stock in a transaction dated Tuesday, May 22nd. The stock was sold at an average price of $50.66, for a total transaction of $4,348,755.72. The disclosure for this sale can be found here. Insiders have sold 125,842 shares of company stock worth $6,832,356 over the last quarter. Insiders own 14.00% of the company’s stock.

TRHC has been the topic of a number of recent analyst reports. BidaskClub raised shares of Tabula Rasa HealthCare from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, April 24th. ValuEngine upgraded shares of Tabula Rasa HealthCare from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. Piper Jaffray Companies reiterated an “overweight” rating and set a $46.00 price target on shares of Tabula Rasa HealthCare in a research note on Wednesday, May 9th. Citigroup reiterated a “buy” rating and set a $57.00 price target on shares of Tabula Rasa HealthCare in a research note on Wednesday, May 9th. Finally, Zacks Investment Research upgraded shares of Tabula Rasa HealthCare from a “sell” rating to a “buy” rating and set a $53.00 price target on the stock in a research note on Tuesday, May 15th. Two analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Tabula Rasa HealthCare presently has a consensus rating of “Buy” and a consensus price target of $55.36.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.

Featured Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Institutional Ownership by Quarter for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply